722 related articles for article (PubMed ID: 24165127)
1. A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice.
Gault VA; Bhat VK; Irwin N; Flatt PR
J Biol Chem; 2013 Dec; 288(49):35581-91. PubMed ID: 24165127
[TBL] [Abstract][Full Text] [Related]
2. A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.
Bhat VK; Kerr BD; Vasu S; Flatt PR; Gault VA
Diabetologia; 2013 Jun; 56(6):1417-24. PubMed ID: 23503814
[TBL] [Abstract][Full Text] [Related]
3. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties.
Bhat VK; Kerr BD; Flatt PR; Gault VA
Biochem Pharmacol; 2013 Jun; 85(11):1655-62. PubMed ID: 23518155
[TBL] [Abstract][Full Text] [Related]
4. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
Parker JC; Lavery KS; Irwin N; Green BD; Greer B; Harriott P; O'Harte FP; Gault VA; Flatt PR
J Endocrinol; 2006 Oct; 191(1):93-100. PubMed ID: 17065392
[TBL] [Abstract][Full Text] [Related]
5. Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice.
McShane LM; Irwin N; O'Flynn D; Franklin ZJ; Hewage CM; O'Harte FP
J Endocrinol; 2016 Jun; 229(3):319-30. PubMed ID: 27098830
[TBL] [Abstract][Full Text] [Related]
6. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
8. Characterisation and antidiabetic utility of a novel hybrid peptide, exendin-4/gastrin/xenin-8-Gln.
Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
Eur J Pharmacol; 2018 Sep; 834():126-135. PubMed ID: 30025814
[TBL] [Abstract][Full Text] [Related]
9. A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice.
Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
Peptides; 2018 Feb; 100():202-211. PubMed ID: 29412820
[TBL] [Abstract][Full Text] [Related]
10. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors.
Hansotia T; Baggio LL; Delmeire D; Hinke SA; Yamada Y; Tsukiyama K; Seino Y; Holst JJ; Schuit F; Drucker DJ
Diabetes; 2004 May; 53(5):1326-35. PubMed ID: 15111503
[TBL] [Abstract][Full Text] [Related]
11. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
Maida A; Hansotia T; Longuet C; Seino Y; Drucker DJ
Gastroenterology; 2009 Dec; 137(6):2146-57. PubMed ID: 19766644
[TBL] [Abstract][Full Text] [Related]
12. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
Liu X; Harada N; Yamane S; Kitajima L; Uchida S; Hamasaki A; Mukai E; Toyoda K; Yamada C; Yamada Y; Seino Y; Inagaki N
Life Sci; 2009 Jun; 84(25-26):876-81. PubMed ID: 19358859
[TBL] [Abstract][Full Text] [Related]
13. Ectopic expression of GIP in pancreatic β-cells maintains enhanced insulin secretion in mice with complete absence of proglucagon-derived peptides.
Fukami A; Seino Y; Ozaki N; Yamamoto M; Sugiyama C; Sakamoto-Miura E; Himeno T; Takagishi Y; Tsunekawa S; Ali S; Drucker DJ; Murata Y; Seino Y; Oiso Y; Hayashi Y
Diabetes; 2013 Feb; 62(2):510-8. PubMed ID: 23099862
[TBL] [Abstract][Full Text] [Related]
14. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
Gault VA; O'Harte FP; Harriott P; Mooney MH; Green BD; Flatt PR
Diabetologia; 2003 Feb; 46(2):222-30. PubMed ID: 12627321
[TBL] [Abstract][Full Text] [Related]
15. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid.
Green BD; Gault VA; Flatt PR; Harriott P; Greer B; O'Harte FP
Arch Biochem Biophys; 2004 Aug; 428(2):136-43. PubMed ID: 15246869
[TBL] [Abstract][Full Text] [Related]
16. An oral GLP-1 and GIP dual receptor agonist improves metabolic disorders in high fat-fed mice.
Ma T; Lu W; Wang Y; Qian P; Tian H; Gao X; Yao W
Eur J Pharmacol; 2022 Jan; 914():174635. PubMed ID: 34800466
[TBL] [Abstract][Full Text] [Related]
17. Metabolic effects of sustained activation of the GLP-1 receptor alone and in combination with background GIP receptor antagonism in high fat-fed mice.
Irwin N; McClean PL; Hunter K; Flatt PR
Diabetes Obes Metab; 2009 Jun; 11(6):603-10. PubMed ID: 19515180
[TBL] [Abstract][Full Text] [Related]
18. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
Gault VA; Kerr BD; Harriott P; Flatt PR
Clin Sci (Lond); 2011 Aug; 121(3):107-17. PubMed ID: 21332446
[TBL] [Abstract][Full Text] [Related]
19. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.
Green BD; Gault VA; Mooney MH; Irwin N; Harriott P; Greer B; Bailey CJ; O'Harte FP; Flatt PR
Biol Chem; 2004 Feb; 385(2):169-77. PubMed ID: 15101559
[TBL] [Abstract][Full Text] [Related]
20. (Val(8))GLP-1-Glu-PAL: a GLP-1 agonist that improves hippocampal neurogenesis, glucose homeostasis, and β-cell function in high-fat-fed mice.
Lennox R; Porter DW; Flatt PR; Gault VA
ChemMedChem; 2013 Apr; 8(4):595-602. PubMed ID: 23138973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
